Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?

A woman with heavy pre-treated ovarian cancer sought consultation regarding additional treatments. The case raises the vexing question of whether there may be a time in the course of the disease process where it is most appropriate to state further anti-neoplastic therapy will not be of clinical uti...

Descripción completa

Detalles Bibliográficos
Autor principal: Markman, Maurie
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Published: March 2010
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918845/
https://www.ncbi.nlm.nih.gov/pubmed/20740161
http://dx.doi.org/10.1159/000295905
_version_ 1782185152461406208
author Markman, Maurie
author_facet Markman, Maurie
author_sort Markman, Maurie
collection PubMed
description A woman with heavy pre-treated ovarian cancer sought consultation regarding additional treatments. The case raises the vexing question of whether there may be a time in the course of the disease process where it is most appropriate to state further anti-neoplastic therapy will not be of clinical utility.
format Text
id pubmed-2918845
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-29188452010-08-25 Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value? Markman, Maurie Case Rep Oncol Published: March 2010 A woman with heavy pre-treated ovarian cancer sought consultation regarding additional treatments. The case raises the vexing question of whether there may be a time in the course of the disease process where it is most appropriate to state further anti-neoplastic therapy will not be of clinical utility. S. Karger AG 2010-03-13 /pmc/articles/PMC2918845/ /pubmed/20740161 http://dx.doi.org/10.1159/000295905 Text en Copyright © 2010 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: March 2010
Markman, Maurie
Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
title Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
title_full Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
title_fullStr Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
title_full_unstemmed Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
title_short Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
title_sort is it time to inform this patient that further antineoplastic drug therapy will not be of clinical value?
topic Published: March 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918845/
https://www.ncbi.nlm.nih.gov/pubmed/20740161
http://dx.doi.org/10.1159/000295905
work_keys_str_mv AT markmanmaurie isittimetoinformthispatientthatfurtherantineoplasticdrugtherapywillnotbeofclinicalvalue

Ejemplares similares